Our results indicated that a high ratio of IL32 expression to pericyte marker expression, such as MCAM, PDGFRB, or ACTA2, was also linked to poor overall survival in NSCLC patients (Figure S1O, Supporting Information). The gene discussed is IL32; the disease is non-small cell lung carcinoma.